Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific director's transaction rather than a financial performance report.
Material Changes
The only material change disclosed is a transaction by a director:
- Director: Mr. James Murdoch
- Action: Purchase of 1,000 Ordinary shares
- Date: November 5, 2009
- Price: £12.23 per share
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share purchase in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total shareholding of Mr. James Murdoch following this purchase.
- Confirm the market price of GlaxoSmithKline plc shares on November 5, 2009, to contextualize the £12.23 transaction price.
- Check for any subsequent filings regarding other director transactions during the same period.